HiPP for Health Care Professionals

HiPP ORGANIC COMBIOTIC^®

Safety is our most important ingredient

Tried-and-tested formula. Evidence-based development.

Based on the latest findings from our human milk research, HiPP’s Research & Development Department has developed HiPP ORGANIC COMBIOTIC^® – a new generation of formulae. With its synbiotic composition of pre- and probiotics, HiPP ORGANIC COMBIOTIC^® promotes the formation of a balanced intestinal microbiota^1,2. It is also fortified with the safe and bioavailable Metafolin^®, which corresponds to the natural folate form (5-MTHF) found in human milk. Optimum protection for non-breastfed babies.

HiPP ORGANIC COMBIOTIC® Products

All product information about our HiPP ORGANIC COMBIOTIC^®.

NEW! A sigh of relief for babies’ tummies: HiPP ORGANIC COMBIOTIC® strengthens the gut-lung axis

Respiratory infections are among the most common diseases in infants. A new study provides further evidence of the positive effect of HiPP ORGANIC COMBIOTIC^® on the intestinal microbiota and a resulting reduction in lower respiratory tract infections.

Our best protection for caesarean-born infants

A positive gut microbiota is especially important for caesarean-born infants.
HiPP ORGANIC COMBIOTIC^® promotes the formation of a balanced intestinal microbiota.

HiPP ORGANIC COMBIOTIC® with Metafolin®

The natural folate form as found in human milk! With breast milk, the infant receives 5-MTHF, the metabolically active form of folate. The logical next step is to also add a folate source to formulae that resembles that in breast milk: HiPP COMBIOTIC^® with Metafolin^® – one step closer to nature’s example.

HiPP ORGANIC COMBIOTIC® Concept

HiPP ORGANIC COMBIOTIC^® withL. fermentum and prebiotic GOS promotes the development of healthy intestinal microbiota and is considered particularly well tolerated. The natural folate form Metafolin^® is immediately available and safe.

Good-to-know

Find out everything you need to know about HiPP formulae and formulae in general. On our website, we present the special features of our formulae and discuss new scientific findings.

References:
¹ Maldonado J et al. JPGN 2012; 54: 55–61.
² Gil-Campos M et al. Pharmacol Res 2012; 65: 231–238.